GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Shiller PE Ratio

Vanda Pharmaceuticals (Vanda Pharmaceuticals) Shiller PE Ratio : 18.10 (As of May. 01, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Shiller PE Ratio?

As of today (2024-05-01), Vanda Pharmaceuticals's current share price is $4.8867. Vanda Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $0.27. Vanda Pharmaceuticals's Shiller PE Ratio for today is 18.10.

The historical rank and industry rank for Vanda Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

VNDA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.44   Med: 38.35   Max: 523
Current: 18.1

During the past years, Vanda Pharmaceuticals's highest Shiller PE Ratio was 523.00. The lowest was 13.44. And the median was 38.35.

VNDA's Shiller PE Ratio is ranked better than
76.67% of 150 companies
in the Biotechnology industry
Industry Median: 34.975 vs VNDA: 18.10

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.040. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.27 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vanda Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Vanda Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Shiller PE Ratio Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 603.17 44.55 15.86

Vanda Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.55 34.74 30.47 17.95 15.86

Competitive Comparison of Vanda Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Vanda Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Shiller PE Ratio falls into.



Vanda Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vanda Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=4.8867/0.27
=18.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Vanda Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.04/129.4194*129.4194
=-0.040

Current CPI (Dec. 2023) = 129.4194.

Vanda Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.790 99.695 -1.026
201406 -0.640 100.560 -0.824
201409 -0.040 100.428 -0.052
201412 1.770 99.070 2.312
201503 -0.240 99.621 -0.312
201506 -0.130 100.684 -0.167
201509 -0.220 100.392 -0.284
201512 -0.350 99.792 -0.454
201603 -0.290 100.470 -0.374
201606 -0.110 101.688 -0.140
201609 -0.010 101.861 -0.013
201612 -0.010 101.863 -0.013
201703 -0.170 102.862 -0.214
201706 -0.030 103.349 -0.038
201709 -0.100 104.136 -0.124
201712 -0.040 104.011 -0.050
201803 0.060 105.290 0.074
201806 0.090 106.317 0.110
201809 0.130 106.507 0.158
201812 0.190 105.998 0.232
201903 -0.010 107.251 -0.012
201906 0.210 108.070 0.251
201909 1.840 108.329 2.198
201912 0.080 108.420 0.095
202003 0.010 108.902 0.012
202006 0.160 108.767 0.190
202009 0.110 109.815 0.130
202012 0.140 109.897 0.165
202103 0.150 111.754 0.174
202106 0.170 114.631 0.192
202109 0.140 115.734 0.157
202112 0.120 117.630 0.132
202203 -0.110 121.301 -0.117
202206 0.050 125.017 0.052
202209 0.060 125.227 0.062
202212 0.120 125.222 0.124
202303 0.060 127.348 0.061
202306 0.030 128.729 0.030
202309 0.002 129.860 0.002
202312 -0.040 129.419 -0.040

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vanda Pharmaceuticals  (NAS:VNDA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Vanda Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Executives
Joakim Wijkstrom officer: SVP, Chief Marketing Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran officer: VP, Acting CFO & Treasurer C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams officer: SVP & General Counsel C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos director, officer: Chief Executive Officer 9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks officer: SVP, Business Development 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins director 1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones officer: Chief Corp. Affairs Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos director 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan director 20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly officer: SVP, CFO, Treasurer & Secretar C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi officer: SVP, General Manager Europe 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341